Massachusetts Institute of Technology, 1986, BS
University of California, San Francisco, 1990, MD
Hematopoietic cell transplantation for severe autoimmune diseases: Autologous and allogeneic transplantation for diseases including systemic sclerosis, multiple sclerosis and aplastic anemia.
Nonmyeloablative hematopoietic cell transplantation: Regimens to reduce the toxicity of allogeneic transplantation, particularly in older patients or patients with medical comorbidities.
Hematopoietic stem cell and T cell gene therapy: Laboratory-based studies on hematopoietic stem cell expansion and genetic correction of underlying disease.
Development of radiation mitigators, for example, to reduce toxicity of gastrointestinal syndrome after irradiation.
Hematopoietic cell transplantation for hematologic malignancies (leukemia, lymphoma and other malignancies) and autoimmune diseases (systemic sclerosis, multiple sclerosis and aplastic anemia).
Treatment of acute and chronic graft-versus-host disease.
Nonmyeloablative conditioning regimens for allogeneic hematopoietic cell transplantation
Protocol 2260 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases
Protocol 2533 A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis
Protocol 2067 Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
Protocol 1990 The Effect of Allogeneic Hematopoietic Cell Transplantation on the Activity and Progression of Multiple Sclerosis
Protocol 1581 Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia – a Multi-Center Trial
Protocol 1948 A Randomized, Open-Label, Phase II/III Multi-Center Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis
Protocol 1997 A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis
“Increasing Stem Cell Numbers While Retaining Stem Cell Function” Ancillary/Collaborative Studies for the NHLBI Progenitor Cell Biology Consortium. Laboratory based project involving ex vivo expansion of CD34+ progenitor cells and gene marking.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.